Meeting
2022 ASCO Genitourinary Cancers Symposium
Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).
Authors
Scott T. Tagawa
Weill Cornell Medicine, New York, NY
Scott T. Tagawa , Joseph Osborne , Matthew Dallos , Jones Nauseef , Cora N. Sternberg , Peter Gregos , Amie Patel , Angela Tan , Sharon Singh , Mahelia Bissassar , Ana M. Molina , Paraskevi Giannakakou , Himisha Beltran , David M. Nanus , Karla V. Ballman , Neil Harrison Bander
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04946370
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr TPS216)
DOI
10.1200/JCO.2022.40.6_suppl.TPS216
Abstract #
TPS216
Poster Bd #
R2
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
First Author: Evan Y. Yu
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY).
First Author: Yu-Wei Chen
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591.
First Author: Michael Philip Sun
Poster
2021 Genitourinary Cancers Symposium
A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).
First Author: A. Oliver Sartor